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Introduction
Fatigue is not the same as weakness and it is an inde-
pendent symptom with an overwhelming sense of tired-
ness, lack of energy, and feeling of exhaustion. The
definition of fatigue is exercise-induced reduction in
the maximal capacity to generate force or power out-
put1 or difficulty in initiation of or sustaining voluntary
activities,2 implying a decrease in performance even in
the absence of permanent weakness. Fatigue mecha-
nisms contain a peripheral origin of muscle tissue and
a central origin of the nervous system.3–5 The physiol-
ogy of exercise-induced fatigue usually contains both
components.4,5
Fatigue is a common complaint in clinics and is
reported in as many as 20% of patients in primary care
settings.2 A high prevalence of fatigue is found in neu-
rological diseases such as stroke,6 multiple sclerosis,7
Parkinson’s disease,8 chronic inflammatory demyeli-
nating polyneuropathy,9 myasthenia gravis,10 facio-
scapulohumeral dystrophy, myotonic dystrophy, and
hereditary motor/sensory neuropathy type I.11
Fatigue is usually underestimated and is generally
investigated in the course of or after recovery from a
disease. However, it may be an early symptom of pa-
tients with neuromuscular disorders and precedes the
onset of weakness.
Myopathy is clinically characterized by muscle
weakness, particularly low muscle endurance or mus-
cle fatigue. Proximal weakness usually is the hallmark
symptom when the diagnosis of myopathy is made.
Here, we report 8 patients whose chief complaint was
fatigue instead of weakness and they had a final diag-
nosis of colchicine myopathy. Some unknown mecha-
nisms might compensate for the injured muscles and
maintain appropriate muscle strength in these patients.
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It has been hypothesized that, in patients with my-
opathy, impaired muscular function might be partially
compensated by central reorganization.12 Transcranial
magnetic stimulation (TMS) is a well-known method
to assess cortical excitability of the motor system.13
Using TMS, it has been shown that nervous system
excitability may be altered in myopathy, and it pres-
ents with a motor disinhibition on cortical and sub-
cortical levels.12 Therefore, we investigated whether
there was a change in the motor cortex to compensate
for the muscular strength in our patients.
Methods
We included 8 patients (males; age range, 42–72 years)
who fulfilled the following criteria: fatigue but with-
out obvious weakness; a history of medication with
colchicine; myopathy shown by electrophysiological
studies; elevated creatine kinase (CK) levels; and clin-
ical improvement after drug discontinuation (Table 1).
History-taking excluded the possibility of hereditary,
depression, and endocrine factors. None of the patients
had any history of neurological diseases. Fifteen normal
subjects (11 males, 4 females) were matched with age
and height in the study. The protocol was approved
by the institutional review board of Taipei Veterans
General Hospital, and all subjects were studied after
their signed informed consents were obtained.
The Fatigue Severity Scale (FSS) was applied to
evaluate the impact of fatigue on subjects (Table 1).
The FSS is a short questionnaire that requires the
subject to rate his/her own level of fatigue.14 To rate
the severity of fatigue symptoms, the FSS question-
naire contains 9 statements. FSS was assessed twice in
each patient, once at diagnosis and again 6 weeks after
drug discontinuation. Subjects were asked to read each
statement and circle a number from 1 to 7, depending
on how accurately it reflected their condition during the
last week and the extent to which they agreed or dis-
agreed that the statement applied to them. A low value
(e.g. 1) indicated strong disagreement with the state-
ment, whereas a high value (e.g. 7) indicated strong
agreement. The FSS was calculated as the mean score of
these 9 items, with answers ranging from 1 (no signs of
fatigue) to 7 (most disabling fatigue).15 Severe fatigue
was defined as a mean FSS score of ≥ 5.0.15
Using a figure-8 coil, TMS was studied with sur-
face electrodes placed on the right first dorsal inter-
osseus muscle. Two Magstim 200 magnetic stimulators
(Magstim Company Ltd., Spring Gardens, Whitland,
Carmarthenshire, Wales, UK) connected to a Bistim
module were used for studies of intracortical inhibi-
tion (ICI) and intracortical facilitation. The data were
recorded by a Neuropack M1 machine (Nihon Kohden
Corp., Tokyo, Japan).
The coil was positioned over the left motor cortex
with the handle pointing to the posterolateral direction,
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Table 1. Clinical data of the 8 patients
Patient
1 2 3 4 5 6 7 8
Age (yr) 48 55 62 72 67 42 51 60
Sex M M M M M M M M
Fatigue duration (mo) 4 7 2 1 1.5 6 1 2.5
Muscle pain Yes No No No No Yes Yes No
Numbness No No No Yes Yes No No Yes
DTR N N D D D N N N
Creatine kinase* (U/L)
Before 253 335 766 468 225 664 534 242
After 126 168 106 68 70 38 90 154
FSS
Before 5.2 5.4 5.4 5.6 5.6 5.4 5.1 5.6
After 2.1 2.3 2.6 2.9 2.6 2.3 2.2 2.7
NCS/neuropathy − − − Mild Mild − − Mild
EMG/myopathy + + + + + + + +
*The normal range of creatine kinase is 27–168 U/L. M = male; DTR = deep tendon reflex; N = normal; D = decreased; Before = before drug discontinuation;
After = after drug discontinuation; FSS = Fatigue Severity Scale; NCS = nerve conduction study; EMG = electromyography.
and the point at which suprathreshold stimuli could
produce the highest amplitude motor responses was
determined. The point was then marked on a cap to
ensure the same stimulating site through the following
experiments. Use of visual and auditory feedback from
an electromyographic machine helped subjects main-
tain muscles at relaxation in the assessment of motor
threshold (MT), motor-evoked potentials (MEP) and
paired TMS studies at constant muscle contraction
during study of the cortical silent period.
MT was defined as the intensity to evoke MEP with
amplitude ≥ 50 μV in at least 5 out of 10 recordings
during muscle relaxation. Using 150% MT, we mea-
sured the peak-to-peak amplitude and the onset latency
of the largest MEP for the further study of motor
central conduction time. The cortical silent period was
also performed with single pulses at 150% MT during
moderate muscle contraction. Ten rectified traces were
recorded with a 500-ms sweep speed and 200–500 μV
sensitivity. Cortical silent period duration was defined
from the turning point of the MEP to the reoccur-
rence of voluntary electromyographic activity. ICI and
intracortical facilitation were studied by using the
method proposed by Kujirai et al.16 During relaxation,
80% MT and 120% MT were applied as the sub-
threshold conditioning and suprathreshold test stimuli,
respectively. Paired stimuli with ISIs of 2, 3, 4, 10, 15
and 20 ms were delivered in a randomized order. At
least 5–10 trials were recorded for each condition.
The amplitude ratios of conditioning and test MEPs
were measured at each ISI.
Nerve conduction studies and electromyography
were conducted in each patient. We measured the com-
pound motor action potentials (M) and F responses
of the first dorsal interosseus. The formula of motor
central conduction time was as follows:
motor central conduction time = MEP − (F + M − 1)/2
The largest amplitude of M and F waves was measured
from peak to peak. We also calculated the amplitude
ratio of MEP/M and F/M in each subject.
The Wilcoxon rank sum test was applied to assess
the difference between patient and control groups,
and the Wilcoxon signed-rank test was used for com-
parison before and after fatiguing exercise. Significance
was considered at the level of p ≤ 0.05.
Results
The main clinical findings are summarized in Table 1.
The course of fatigue was insidious and progressive
(mean, 3.1 ± 2.3 months; range, 1–7 months). The
plasma CK value of each patient returned to the nor-
mal range 4 weeks after drug discontinuation (before
discontinuation, 435.9 ± 206.1 U/L; after discontinua-
tion, 102.5 ± 44.8 U/L; p = 0.0009; Table 1). Electro-
physiological results were consistent with myopathy
in 8 patients and mild axonal neuropathy in 3. These
electromyographic findings rapidly resolved 6 weeks
after diagnosis and management. Repetitive stimula-
tion at 3 Hz was performed in some patients and this
did not show a significant decrement or evidence of
neuromuscular junction dysfunction. The C-reactive
protein level was not elevated in any patient.
Severe fatigue (FSS ≥ 5) was noted in each patient
(patients, 5.41±0.19; controls, 2.12±0.45; p=0.0004;
Table 1). Most of the patients described an inability
to maintain a sustained effort, which was ameliorated
by rest. All of the patients described fatigue as their
most disabling symptom, sometimes preventing them
from carrying out professional as well as sociofamilial
activities. Before discontinuation, FSS was higher in
patients than in controls (2.12±0.45; p=0.0004). After
discontinuation, they all had a rapid recovery, with 
a FSS from 5.41 ± 0.19 to 2.46 ± 0.28 (p = 0.0009).
Electrophysiological results did not show any significant
group difference (Table 2).
Discussion
The diagnosis of myopathy in our patients was made
1–7 months after the onset of fatigue. It was difficult
for physicians to make an early diagnosis with only a
nonspecific complaint of fatigue. Other causes should
be considered in our patients in the differential diag-
nosis of fatigue. Two of our patients (patients 2 and 6)
had had fatigue for more than 6 months. Chronic
fatigue syndrome was considered for these patients in
the differential diagnosis. However, fatigue could be
alleviated by rest in these patients but this is not the
case for chronic fatigue syndrome.17 Therefore, these
2 patients did not have chronic fatigue syndrome.
Neuropathy was noted in 3 patients whose FSS and
CK values decreased after discontinuation but nerve
conduction study results did not improve. Therefore,
neuropathy could not account for their fatigue. We
could not completely exclude the possibilities of anxi-
ety, depression or sleep disturbance, which also might
play a role in the symptom of fatigue. However, reso-
lution of the fatigue after colchicine discontinuation
strongly supports the diagnosis of drug-induced my-
opathy. Our report indicates that fatigue may precede
weakness and present as the initial manifestation of
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drug-induced myopathy. Early recognition may shorten
the length and severity of morbidity.
The FSS showed that our patients had signific-
ant fatigue before therapy. However, our TMS studies
did not show any significant difference between
patient and control groups. Our results indicated that
fatigue of our patients was due to the muscle itself,
i.e. muscle fatigue. This finding is in contrast with 
the report of Liepert et al,12 who studied short ICI
(SICI) for cortical magnetic stimulation and F
response for electrical stimulation in 10 patients with
myopathy. They found a reduction of ICI, enhanced
F amplitudes, and an increased F/M ratio in myo-
pathic patients, and they concluded that their findings
could be explained by a motor disinhibition on corti-
cal and subcortical levels. The difference between the
2 studies could, in part, be due to the different meth-
ods and different materials. Colchicine myopathy is
an acquired disease. However, patients in Liepert 
et al’s study12 included 6 facioscapulohumeral muscu-
lar dystrophy, 2 limb girdle muscular dystrophy, 1
emerinopathy, and 1 multicore disease. Some of their
patients had decreased strength of proximal muscles
and limited arm abduction, although the hand func-
tion of their patients showed normal strength, similar
to our study. The disease duration might have been
another variable and seemed to be longer in patients
in their study.12
Liepert et al12 showed that SICI was decreased in
different muscle diseases, indicating that the effect of
myopathy on the brain was independent of its pathol-
ogy and entity. However, in other series, SICI was
not reduced in polymyositits,18 limb girdle muscular
dystrophy,18 Duchenne muscular dystrophy,19 or in our
patients. There are controversial findings on Duchenne
muscular dystrophy. For instance, Di Lazzaro et al20
found reduced cortical excitability with a higher MT,
but this was not found by Yayla et al.19 Another study
using paired stimuli of somatosensory-evoked poten-
tials to assess cortical excitability showed that hyper-
excitability was found only in patients with myotonic
dystrophy but not in facioscapulohumeral muscular
dystrophy.21 Therefore, the effect of muscle diseases
on the brain is still controversial.
In conclusion, our results failed to show a central
compensative mechanism for strength in our colchicine
myopathy patients. Muscle fatigue may precede weak-
ness as an early symptom of myopathy. Plasma CK levels
should be measured to rule out the possibility of mus-
cle injury when a patient presents complaining of fa-
tigue. Early recognition and discontinuation of affected
medications may shorten the course of morbidity.
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Table 2. Electrophysiological data*
Patients (n = 8) Controls (n = 15) p
Motor NCS
M latency (ms) 3.84 ± 0.22 3.74 ± 0.20 0.30
M responses (mV) 19.96 ± 1.44 20.56 ± 1.05 0.44
F latency (ms) 26.23 ± 1.13 27.11 ± 0.86 0.08
F responses (mV) 0.22 ± 0.10 0.26 ± 0.12 0.50
F/M ratio (%) 1.10 ± 0.59 1.24 ± 0.55 0.58
TMS/single stimulation
Motor threshold (%) 42.8 ± 5.8 40.8 ± 6.1 0.60
MEP latency (ms) 21.69 ± 1.31 22.28 ± 0.98 0.30
MEP amplitude (mV) 2.44 ± 0.81 2.24 ± 0.64 0.70
CCT (ms) 7.11 ± 0.75 7.35 ± 0.55 0.35
MEP/M response (%) 12.18 ± 3.65 10.82 ± 2.79 0.48
Silent period (ms) 141.9 ± 11.1 141.7 ± 11.9 0.99
TMS/paired stimuli
ISI 2 ms (%) 32.06 ± 5.83 31.68 ± 4.98 0.95
ISI 3 ms (%) 33.34 ± 7.75 34.61 ± 4.31 0.63
ISI 4 ms (%) 42.36 ± 7.86 40.85 ± 7.31 0.61
ISI 10 ms (%) 125.6 ± 10.4 120.7 ± 11.5 0.35
ISI 15 ms (%) 136.5 ± 10.4 132.5 ± 7.3 0.42
ISI 20 ms (%) 144.1 ± 12.9 139.4 ± 8.2 0.37
*Data are presented as mean ± standard deviation. NCS = nerve conduction study; M = motor action potentials; F = F response; TMS = transcranial magnetic
stimulation; MEP = motor-evoked potential; CCT = central conduction time; ISI = interstimulus interval.
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